Korean biotech companies to present latest cancer immunotherapies at SITC 2024
Several Korean biotechnology companies are set to showcase their latest immunotherapy innovations at the Society for Immunotherapy of Cancer (SITC) 2024 conference, scheduled for Nov. 6-10 in Houston, Texas, the U.S.
SITC, established in 1984, is the world's largest conference dedicated to cancer immunotherapy, bringing together over 4,600 clinicians, scientists, and researchers from 63 countries to advance cancer treatment through immunotherapy development.
Hanmi Pharm will present preclinical results for their novel immunomodulatory cancer drug, LAPS IL-2 Analog (HM16390), which has demonstrated complete remission in treating malignant tumors in animals.
The company will also unveil the clinical background and design of BH3120, a next-generation cancer immunotherapy utilizing their proprietary Pentambody platform technology.
Y-Biologics has secured two poster presentations, including research on AR148, a solid cancer that applies its TGFβ SelecTrap technology.
The company's AR148, designed through AI modeling, selectively inhibits TGFβ 1 and 3 with lower toxicity than existing treatments. They will also present findings on AR092, a T-cell bispecific antibody showing promising results in solid tumors.
NeoImmuneTech will showcase two research achievements related to their NT-I7 (ingredient: efineptakin alfa) therapy. The presentations will include biomarker analysis results from their NIT-110 clinical trial, which combines NT-I7 with Keytruda, and research led by Dr. Rebecca Obeng on IL-7's role in reconstructing the tumor immune microenvironment in lung adenocarcinoma.
STCube will present detailed phase I clinical trial results for nelmastobart, its anti-BTN1A1 antibody. The study, involving 47 patients with advanced solid tumors, demonstrated promising safety profiles with only mild adverse events in most cases.
The company is currently conducting phase 1b/2 trials for small cell lung cancer and colorectal cancer treatments.
MedPacto will present clinical data from their combination therapy study of vactosertib for advanced non-small cell lung cancer (NSCLC). The phase 1b/2a trial results demonstrate synergistic effects when vactosertib is combined with durvalumab, with analysis focusing on treatment efficacy according to PD-L1 expression levels.
Other companies that will unveil research during SITC 2024 include Lunit and GC Cell.
"This year's SITC conference represents a significant opportunity for Korean biotech companies to demonstrate their growing influence in the global immunotherapy landscape," an industry official told Korea Biomedical Review. "The research being presented underscores Korea's emerging leadership in innovative cancer treatments."